Avita Medical Patent Validated In Eleven European Countries

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - September 02, 2015) - Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that one of its European patents has been validated in Austria, Belgium, France, Germany, Great Britain, Italy, the Netherlands, Portugal, Spain, Sweden and Turkey.

Patent EP 2 343 079 covers the broad use of the company's cell suspension preparation device, ReCell®, and relates to a simple, rapid and cost-effective technique for grafting cells. In particular, the patent covers a device for preparing a suspension of cells using a tissue sample obtained from a donor site.

"This patent is an important addition to our intellectual property estate, which further strengthens Avita's position as a leader in skin repair technology," said Adam Kelliher, Chief Executive Officer of Avita Medical Ltd. "We are pleased that Avita's ownership and inventorship of the ReCell® technology is now recognized in these eleven countries, and believe that the protections it affords represent an important step in our efforts to maximize the value of our proprietary regenerative platform."

Avita technology has thus far been applied to the treatment of chronic wounds, severe burns and skin discoloration.

ReCell® is Avita Medical's unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. A pivotal U.S. trial is underway, with patient enrollment completion anticipated by the end of 2015. To learn more, visit www.avitamedical.com.


Avita Medical Ltd
Adam Kelliher
Chief Executive Officer
Phone: +44 (0) 1763 269 772

Avita Medical Ltd
Tim Rooney
Chief Financial Officer
Phone: + 1 (818) 356-9400

Avita Medical Ltd
Gabriel Chiappini
Company Secretary
Phone: +61(0) 8 9474 7738

The Ruth Group
Lee Roth, Investor Relations
Kirsten Thomas, Public Relations
Phone: +1 (646) 536-7012 / 7014
/ kthomas@theruthgroup.com

Help employers find you! Check out all the jobs and post your resume.

Back to news